PTA takes action against digital content involving illegal therapeutic goods sale
2 min readThe Pakistan Telecommunication Authority (PTA) came into action against the illegal sale of therapeutic goods via websites and social media pages and got the content removed, according to a press statement issued by the authority on Wednesday.
The therapeutic goods may include medicines, medical devices, and vaccines, it was learnt.
PTA said in the statement that it initiated action against websites and social media pages that were involved in the sale of unauthorised and unregistered therapeutic goods upon receiving a request from the Drug Regulatory Authority of Pakistan (DRAP).
“PTA undertook necessary enforcement measures to restrict access to the identified content. The concerned websites have confirmed removal of the illegal products, while the matter is being actively pursued with social media platforms for early takedown of reported pages and groups,” the statement read.
“PTA remains committed to supporting national regulatory efforts to safeguard public health and prevent misuse of digital platforms, and will continue to take timely action in accordance with applicable laws and regulations.”
Meanwhile, the local drug manufacturers have warned that the Pakistani market could see an uptick in the sales of smuggled and counterfeited medicines, as authorities concerned have not notified price-tagging for new and advanced medications, including for cancer, heart and blood pressure over the past year.
According to the manufacturers, they have applied to the government to set retail prices for around 80 to 90 medicines over the last year.
DRAP and the pricing committee have already approved the prices for introducing the new medicines. However, the highest authority in the country, the Federal Cabinet, which is headed by the Prime Minister of Pakistan, is yet to give its final approval, that is prolonging for quite a long period.
For the latest news, follow us on Twitter @Aaj_Urdu. We are also on Facebook, Instagram and YouTube.





















